Skip to content
RDL Network logo
Modulation of NK, T, & B cell sub-populations by Pomalidomide predicts favorable progression-free survival (PFS): Results from a large randomized clinical trial in relapsed/refractory myeloma. — Prabhal Rao (2019) | RDL Network